Candida Cristina Quarta
Cristina Quarta is a Senior Medical Director in Clinical Development and Translational Sciences at Alexion, AstraZeneca Rare Disease, based in Boston, holding a PhD in medical sciences from the University of Bologna and specialising in Cardiology.
During her tenure at Alexion, Cristina has served as the Global Clinical Development Lead for groundbreaking programs in the field of systemic amyloidosis, including the CAEL-101 and ALXN2220 monoclonal antibody therapies for amyloid depletion, and the ALXN2060 TTR stabiliser for Japanese patients with ATTR cardiomyopathy.
Prior to their time at Alexion, Cristina spent 15 years working in the field of systemic amyloidosis and rare cardiomyopathies. Between 2015 and 2019, she worked as a consultant cardiologist at the National Amyloidosis Centre & Royal Free Hospital in London, United Kingdom, where she provided clinical expertise, collaborated with pharmaceutical companies, and led research projects dedicated to understanding and treating cardiac amyloidosis.
Between 2012 and 2014, during her tenure as a Research Fellow at Harvard Medical School & Brigham and Women’s Hospital in Boston, Massachusetts, she managed echocardiographic projects and collaborated with the Amyloid Center at Brigham and Boston University, contributing to cutting-edge research and clinical trials.
Cristina published over 80 papers in peer-reviewed journals with high IF, and she has kept her active involvement in renowned professional societies.